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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYAutosomal recessive osteopetrosis is a human bone disease mainly caused by TCIRG1 gene mutations that prevent osteoclasts resorbing
activity, recapitulated by the oc/ocmouse model. Bone marrow transplantation is the only available treatment, limited by the need for a
matched donor. The use of induced pluripotent stem cells (iPSCs) as an unlimited source of autologous cells to generate gene corrected
osteoclasts might represent a powerful alternative. We generated iPSCs from oc/oc mice, corrected the mutation using a BAC carrying
the entire Tcirg1 gene locus as a template for homologous recombination, and induced hematopoietic differentiation. Similarly to phys-
iologic fetal hematopoiesis, iPSC-derived CD41+ cells gradually gave rise to CD45+ cells, which comprised bothmature myeloid cells and
high proliferative potential colony-forming cells. Finally, we differentiated the gene corrected iPSC-derivedmyeloid cells into osteoclasts
with rescued bone resorbing activity. These results are promising for a future translation into the human clinical setting.INTRODUCTION
Bone is a highly specialized tissue under constant renewal
that takes place through coordinated balanced destruction
and reconstruction, respectively, played by osteoclasts and
osteoblasts, known as bone remodeling (Teitelbaum and
Ross, 2003). Osteoclasts are large fused multinucleated
cells deriving from myeloid precursors belonging to the
hematopoietic lineage. Defects in their resorbing activity
lead to autosomal recessive osteopetrosis (ARO), a rare
life-threatening bone disease that causes increased bone
density, decreased bone strength with risk of multiple frac-
tures, and progressive narrowing of themedullary cavity. In
turn, these defects lead to anemia, thrombocytopenia, and
compensatory extramedullary hematopoiesis and in some
cases may associate to immune dysfunction (Sobacchi
et al., 2013). The most frequently mutated gene is the
T cell immune regulator 1 (TCIRG1), encoding the a3 sub-
unit of the vacuolar-type proton transporting ATPase
pump (Frattini et al., 2000), which mediates the acidifica-
tion of the bone/osteoclast interface. The spontaneous
mutant oc/oc mouse bears a deletion in the Tcirg1 gene
and well mimics the clinical features of human osteopetro-
sis (Scimeca et al., 2000). To date, the only available treat-
ment for ARO is the hematopoietic stem cell (HSC) trans-
plantation (A.S. Schulz et al., 2013, abstract, 39th Annual558 Stem Cell Reports j Vol. 5 j 558–568 j October 13, 2015 j ª2015 The AMeeting of the European Group for Blood and Marrow
Transplantation). However, several patients do not have
access to grafts from HLA-matched siblings, a treatment
that ensures the best 5-year disease-free survival rate
(62% versus 40% with alternative donor transplantation
including HLA-matched unrelated) (Orchard et al., 2015).
To overcome the problem of donor availability, generation
of autologous corrected HSCs followed by transplantation
might represent a valid therapeutic option. HSC gene ther-
apy is being utilized with efficacy in a number of genetic
diseases (Aiuti et al., 2009, 2013; Biffi et al., 2013; Cavaz-
zana-Calvo et al., 2010; Hacein-Bey-Abina et al., 2010).
However, the use of integrating viral vectors to deliver
wild-type (WT) cDNAdoes not allow to restore the integrity
of the locus. For this reason, HSCs generated from iPSCs
(Robinton and Daley, 2012; Takahashi and Yamanaka,
2006) might represent an alternative source of autologous
donor cells, since iPSCs can be easily expanded in large
quantities, manipulated to perform gene targeting, and
then differentiated into corrected autologous HSCs. Initial
experiments on gene targeting in human CD34+ cells
by delivering artificial endonucleases and donor DNA tem-
plate have recently been performedwith success, providing
a new promising technology (Genovese et al., 2014).
Nevertheless, the relative low efficiency by which gene
targeting occurs in long-term repopulating HSCs anduthors
progenitors may limit application of this technology to
diseases in which there is a strong in vivo selective advan-
tage of the corrected cells. Generation of iPSCs from
patients who do not have access to an HLA-identical
sibling donor could allow their site-specific genetic correc-
tion by homologous recombination, followed by differen-
tiation toward hematopoietic progenitors and autologous
transplantation.
In the present study, we present a step-by-step strategy
by which gene-corrected osteopetrotic iPSCs were used to
generate hematopoietic progenitor cells able to give rise
in vitro to functional osteoclasts, thus providing a proof
of principle for an autologous cell therapy approach to treat
osteopetrosis and potentially other genetic blood disorders
(Hanna et al., 2007).RESULTS
Derivation of Vector-free iPSCs from Osteopetrotic
Mice
To obtain iPSCs from WT and oc/oc mouse fibroblasts, we
used a third-generation, Cre-excisable lentiviral vector ex-
pressing a single cistron encoding for Oct4, Sox2, and Klf4
under the control of the spleen focus-forming virus pro-
moter (sffv). Four weeks after a single transduction at
low multiplicity of infection (MOI = 1), colonies with em-
bryonic stem (ES) cell-like morphology (nine fromWTand
19 from oc/oc fibroblasts) were picked and expanded. Total
DNA was extracted from each clone to perform vector
copy number (VCN) analysis. Three clones for each geno-
type (WT or oc/oc) with the lowest VCN and with a normal
mouse chromosome complement (2n = 40) were selected
for subsequent analysis. With the aim of obtaining viral
vector-free cell lines, excision of the reprogramming lenti-
viral vector was achieved by transient expression of the
Cre recombinase in the six clones. After sub-cloning, six
lines with a VCN equal to zero were selected for further
characterization: WT iPSCs 6.25.2, 6.25.39, and 6.25.68
(hereafter referred to as WT 2, WT 39, and WT 68, respec-
tively) and oc/oc iPSCs 13.62, 13.65, and 16.74 (oc/oc 62,
oc/oc 65, and oc/oc 74, respectively) (Figure 1A). The clones
displayed stemness characteristics that persisted after the
excision procedure. They expressed alkaline phosphatase
(Figure 1B; Figure S1A) and other typical stemness markers
as revealed by immunofluorescence (Figure 1C; Figure S1B)
and RT-PCR (data not shown). Cytogenetic analysis
showed a normal karyotype (Figure 1D; Figure S1C). All
clones were bona fide pluripotent as assessed by their abil-
ity to differentiate toward the three germ layers in vitro
(Figure 1E; data not shown) and in vivo (Figures 1F and
S1D), forming teratomas upon subcutaneous injection
into NSG mice.Stem CellIn conclusion, we were able to generate Tcirg/ iPSC
clones from oc/oc mice, with phenotypic and functional
characteristics comparable to those displayed by iPSCs ob-
tained fromWTmice. All tested iPSC clones were free from
the reprogramming vector, contained a normal set of chro-
mosomes, and maintained stemness and pluripotency.
Efficient BAC-Mediated Tcirg1 Gene Correction in oc/
oc iPSCs with Preserved Stemness and Pluripotency
The oc/oc iPSC lines were transfected with a Bacterial Artifi-
cial Chromosome (BAC) containing the full-length Tcirg1
gene, including its 50- and 30-flanking regions, with the
aim of replacing one of themutated alleles with the correct
form. To select cells with BAC insertion, we engineered the
donor vector to introduce a FRT-flanked neomycin resis-
tance cassette (neo) into the intron 10 (Figure 2A). Trans-
fected cells were cultured in the presence of neomycin
and resistant iPSC colonies were picked and analyzed for
the presence of the corrected Tcirg1 allele by PCR analysis
on genomic DNA and for expression of the corrected tran-
script by RT-PCR (data not shown). iPSC clones that were
positive for both PCRs were then subjected to fluorescence
in situ hybridization (FISH) analysis using the BAC as probe
to test for the correct sub-centromeric localization of the
BAC on chromosome 19 and for screening of possible off-
target integrations (Figures 2B and 2C). In the three clones
named 13.62.18, 13.62.28, and 16.74.32 (hereafter referred
to as 18-BAC, 28-BAC, and 32-BAC), whose expression of
the corrected Tcirg1 gene is shown in Figure 2D, the BAC
probe was localized only to chromosome 19 (Figure 2C),
while other clones were found to have random integra-
tions (Figure S2A). Despite these manipulations, 18-BAC,
28-BAC, and 32-BAC iPSC clones maintained a normal
karyotype (Figure S2B) as well as their pluripotency charac-
teristics, as shown by the expression of stemness markers
(Figures S2C and S2D), the capacity to form embryoid
bodies (EBs) containing the three germ layers, and the
ability to generate teratomas in NSG mice (Figure S2E).
Moreover, beating cardiomyocytes were obtained in all
iPSC lines tested (data not shown). When injected in blas-
tocysts, clone 32-BAC contributed to chimera formation
(Figure S2F).
Because of the high degree of homology between the
BAC and the endogenous Tcirg1 locus, we were unable to
map the exact location of the recombination between
these two sequences by standard Southern blot or PCR
analysis. However, we reasoned that clones that underwent
homologous recombination should not contain sequences
belonging to the BAC backbone. To assess whether vector
sequences were absent in BAC-corrected iPSC clones, we
performed PCRs to detect a portion of chloramphenicol
resistance (CmR) and the yeast HIS3 gene (Figure 2E), as
an indirect evidence of targeted correction, as previouslyReports j Vol. 5 j 558–568 j October 13, 2015 j ª2015 The Authors 559
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Figure 1. Generation and Characteriza-
tion of iPSCs from WT and oc/oc Mice
(A) Experimental outline for the generation
of WT and oc/oc iPSC clones with excised
reprogramming vector (VCN = 0) and car-
rying the correct chromosome complement
(see text for details).
(B) Expression of alkaline phosphatase on
WT and oc/oc iPSC colonies.
(C) Expression of Oct4, Sox2, Nanog, and
SSEA-1 on WT and oc/oc iPSCs as revealed by
immunofluorescence. Nuclei are stained
with DAPI. Scale bars, 100 mm.
(D) Karyotype analysis of WT and oc/oc iPSC
clones.
(E) Generation of the three germ layers
in vitro by differentiated WT and oc/oc
iPSCs is revealed by immunofluorescence.
Expression of Brachyury, AFP, and Nestin
indicate formation of mesoderm, endoderm,
and ectoderm, respectively. Scale bars,
50 mm.
(F) H&E staining of teratomas generated
after subcutaneous injection of WT and
oc/oc iPSC clones into NSG mice, demon-
strating differentiation into the three germ
layer derivatives (i, mesoderm-cartilage; ii,
mesoderm-adipose tissue; iii, endoderm-
glandular structure; iv, endoderm-glandular
structures (intestinal paneth or pancreatic
acinar cell-like); v, ectoderm-primitive
and mature neuroepithelium; vi, ectoderm-
primitive neuroepithelium). Scale bars,
50 mm.
See also Figure S1.
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Figure 2. Correction of Tcirg1 Mutation in oc/oc iPSCs
(A) Upper lane: schematic representation of the BAC used for the gene targeting, containing the 11-kb Tcirg1 locus plus its 50 and 30
flanking regions (55 and 78 kb, respectively), as well as CmR and HIS3 genes belonging to the BAC backbone. Middle and lower lanes:
schematic representation of the 1.6-kb deletion in genomic DNA present in oc/oc mutants compared with the WT genomic region. oc/oc
mice are homozygous for the mutation.
(B) Experimental outline for generating gene-corrected oc/oc iPSC clones (see text for details). Only clones containing and expressing
corrected Tcirg1, as assessed by PCR on genomic DNA and by RT-PCR, were subjected to FISH and karyotype analyses.
(C) Representative metaphase spreads after FISH using the BAC as probe (red), which hybridizes with the BAC-inserted fragment as well as
with the mutated form of Tcirg1. White arrows indicate the presence of the probe only on the two 19 chromosomes in clones 18-BAC, 28-
BAC, and 32-BAC, in a sub-centromeric localization corresponding to the endogenous Tcirg1 location. Since these clones were previously
screened by PCR for the presence of the correct Tcirg1 gene, the presence of two signals in the expected position suggests that at least one
of the two alleles was targeted. Chromosomes were counterstained by DAPI (blue). Scale bars, 5 mm.
(D) RT-PCR analysis for detection of Tcirg1 expression in the WT 39 iPSC clone (used as a positive control), in the oc/oc 74 iPSC clone
(negative control), and in the three corrected oc/oc iPSC clones, using the primers represented by red arrows in (A). Mouse Gapdh was used
as housekeeping control.
(E) PCR analysis for detection of HIS3 and CmR backbone sequences into the genome of iPSC clones. First lane: the positive control showing
the PCR product obtained from the BAC; second lane: the WT iPSC 39 clone used as a negative control; third and fourth lanes: 18-BAC and
32-BAC devoid of the tested backbone sequences. These sequences were absent also in 28-BAC, which was tested separately (data not
shown). The last two lanes show a 168-bp fragment of the CmR and a 191-bp fragment of HIS3 gene obtained in two clones previously
discarded due to the BAC insertion in other chromosomes.
See also Figure S2.
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described (Howden et al., 2011). By this assay, we
confirmed the absence of backbone sequences in the three
selected clones, while these sequences were detected in
clones where the BAC was mapped by FISH to other
different portions of the genome. This suggests, although
does not formally prove, that BAC integrated via homolo-
gous recombination in the targeted locus.
In conclusion, we successfully corrected Tcirg1 muta-
tion in oc/oc iPSCs without affecting their stem cell
characteristics.
BAC-Corrected iPSCs Can Be Successfully
Differentiated into Hematopoietic Early Progenitor
Cells
Amultistep procedure was undertaken to generate hemato-
poietic progenitors fromWT, oc/oc, and BAC-corrected oc/oc
iPSC lines. Pluripotent cells were induced to form EBs
through the ‘‘hanging-drop’’ method. Two days later, EBs
were transferred into tissue-culture treated plates where
they adhered in the presence of BMP4, VEGF, and growth
factors inducing hematopoietic differentiation (inter-
leukin-3 [IL-3], IL-6, SCF, Flt3-ligand, GM-CSF). Hemato-
poietic cell clusters appeared starting from day 8 of culture
and progressively increased in number and size up to day
15 (data not shown).When immuno-magnetically purified
cKit+ cells obtained from these cultures were plated in
methylcellulose, they gave rise to erythroid, myeloid, and
high proliferative potential mixed colonies containing
monocytes, macrophages, granulocytes, and erythroblasts,
indicating the presence of multi-potent and/or oligo-
potent progenitors (Figure 3A). The presence of cells at
different stages of the hematopoietic differentiation was
further confirmed by fluorescence-activated cell sorting
(FACS) analysis performed on pooled colonies (Figure 3A).
The proportion of myeloid precursors was similar in
colonies generated by WT and BAC-corrected iPSCs. Flow
cytometry analysis performed prior to purification of
cKit+ cells confirmed the presence of hematopoietic lineage
cells in cultures originated from all iPSC clones, as revealed
by the expression of the pan-hematopoietic marker CD45
in a proportion of the cells (Figure 3B). Most of the
CD45+ cells co-expressed the CD11b myeloid cell marker,
suggesting that this culture condition potentially sup-
ported the development of osteoclast progenitors, the rele-
vant cell type in our model (Figure 3B).
We next performed flow cytometry analysis at different
time points during hematopoietic differentiation of iPSC
to identify the optimal cell-culture length to obtain the
highest yield of CD45+ cells to be further differentiated
into osteoclasts, without losing early progenitors. Interest-
ingly, time course analysis revealed an in vitro differentia-
tion pattern reminiscent of physiologic fetal hematopoie-
sis. CD41+ cells, including CD41hi and especially CD41low562 Stem Cell Reports j Vol. 5 j 558–568 j October 13, 2015 j ª2015 The Acells, which have been shown to include definitive HSCs
in themouse embryo (Robin et al., 2011), were abundantly
present at day 8 and subsequently were gradually replaced
by CD45+ cells, typical of adult-type hematopoiesis (Fig-
ure 3C). Importantly, all iPSCs gave rise to CD41+ and
CD45+ cells with similar yield and kinetics. The maximum
yields of myeloid CD45+CD11b+ cells were reached at days
10–12, with no major differences among the different
clones, with the exception of a tendency to a slower ki-
netics of myeloid maturation from uncorrected oc/oc iPSC
that is significant at day 10 (Figure 3D).
Overall, the gene correction procedure preserved the he-
matopoietic differentiation capacity of oc/oc-derived iPSCs.
Gene-Corrected oc/oc-Derived iPSCs Generate
Functional Osteoclasts with Resorbing Activity
To demonstrate that gene-corrected iPSCs from oc/oc mice
were functionally competent, hematopoietic cells gener-
ated by all iPSC lines were forced to differentiate in vitro
intomultinucleated osteoclasts and assayed for their capac-
ity to resorb dentine, a specific test for osteoclast function.
In detail, at the end of the hematopoietic differentiation
procedure, CD45+ cells were purified by immuno-magnetic
beads and cultured in the presence of M-CSF and SCF to
further stimulate the proliferation of progenitor cells and
to drive monocyte differentiation. Six days later, we re-
placed SCF with RANKL to induce the fusion of pre-osteo-
clasts and the activation ofmature osteoclasts. The identity
of osteoclast cells in culture was confirmed by the tartrate
resistant alkaline phosphatase (TRAP) staining and the
count of the nuclei (>3). iPSCs obtained fromWTmice suc-
cessfully generated TRAP+ multinucleated osteoclasts
similar to those obtained from the spleen or BM of adult
WT mice (Figure 4A, i–iii). Importantly, these osteoclasts
were equally able to efficiently resorb dentine, indicating
the ability of iPSCs to undergo terminal differentiation to
a very specialized cell type (Figure 4B, i and ii). iPSCs
derived from oc/oc mice were also able to differentiate
into osteoclasts, which were phenotypically similar to
those obtained from oc/oc mice fresh splenocytes (Fig-
ure 4A, iv and v). As expected, oc/oc osteoclasts, either
spleen derived (data not shown) or iPSC derived, were un-
able to resorb dentine (Figure 4B, iii). We then performed
the same experiment with hematopoietic cells obtained
from gene-corrected oc/oc iPSCs, after removing the neo
cassette from the 18-BAC iPSC clone by transient transfec-
tion of the Flp recombinase (thus obtaining the 18-BACf
clone), to avoid possible interference of the neo sequence
with the high expression of the Tcirg1 protein occurring
in mature resorbing osteoclasts. Remarkably, we obtained
a complete rescue of the capacity to resorb dentine (Figures
4A, vi, and 4B, iv), demonstrating that BAC-mediated
correction of the mutated Tcirg1 was successful.uthors
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Figure 3. Differentiation of iPSCs toward
the Hematopoietic Lineage
(A) Methylcellulose colony assays were per-
formed at the end of the hematopoietic differ-
entiation procedure with cKit+ cells purified
from cultures initiated by WT, oc/oc, or oc/oc
BAC-corrected iPSCs. Pictures on the left
represent erythroid (BFU-E), myeloid (CFU-GM
and CFU-M), and mixed (CFU-GEMM) colonies
obtained from differentiated WT iPSCs; pictures
on the right show CFU-GM colonies from one
oc/oc and one corrected iPSC clone (scale bars,
400 mm). Colony assays were performed with all
nine clones, for a total of 16–30 independent
replicates/group (WT, oc/oc, and BAC-cor-
rected). Once scored, some individual colonies
were cytospun and stained with May-Grunwald
and Giemsa. The insert shows a representa-
tive example of a cytospin preparation of a
CFU-GEMM colony showing macrophages (M),
monocytes (Mo), granulocytes (Gr), and eryth-
rocytes (Er) (scale bar, 50 mm). In other exper-
iments, FACS analysis was performed on pooled
colonies to confirm the presence of TER119+
erythroid cells, CD11b+F4/80+ macrophages,
TER119–CD11b+Ly6G+ polymorphonucleated
(PMN) granulocytes. On the PMN– gate
monoblasts, Pro-monocytes and monocytes
were defined as CD31+Ly6C–, CD31+Ly6C+, and
CD31–Ly6C+, respectively. Three clones for each
group (WT, oc/oc and BAC-corrected) were used,
and results are pooled (five to 15 independent
replicates/group) and shown in the bar graph.
(B) Representative FACS analyses showing the
expression of the CD45 pan-hematopoietic and
the CD11b myeloid cell marker at day 12 of cul-
ture ofWT,oc/oc, and corrected iPSC-derived EBs
induced to differentiate toward the hematopoi-
etic lineage. Numbers in the FACS plots indicate
percentages among alive cells. Negative control
is represented in the left contour plot.
(C) Upper panels: representative time course
FACS analysis showing the expression of CD41
and CD45 hematopoietic markers at different
time points of the differentiation protocol of
one BAC-corrected iPSC clone. Upper contour
plots show the control. Results from all cell
lines are summarized and quantified in the bar
graphs, using all nine clones. For each time
point from three to 14 independent experi-
ments were performed.
(D) The graph shows the percentage of CD11b+
cells within CD45+-gated cells in all iPSC
clones. For each time point from three to 14
independent experiments were performed.
Error bars in all bar graphs indicate SEM. Sig-
nificance of differences was determined by
Mann-Whitney test. *p < 0.03; **p < 0.005.
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Figure 4. Differentiated iPSCs Generate
Functional Osteoclasts
(A) Images of TRAP+ osteoclasts derived
from iPSCs (i, iv, and vi) and from fresh
mouse tissues (ii and v, spleen; iii, BM).
Osteoclasts are defined as giant, multi-
nucleated TRAP+ cells. Results are repre-
sentative of at least three independent
experiments/group. Scale bars, 100 mm.
(B) Representative images of dentine discs
stained with toluidine blue, showing the
presence of resorption pits in dentine discs
previously seeded with osteoclast pre-
cursors obtained from WT or BAC-corrected
oc/oc iPSCs (i and iv, respectively) and from
the BM of a WT mouse (ii), but not in discs
seeded with the non-corrected oc/oc 62 iPSC
clone (iii). Results are representative of at
least three independent experiments/
group. Scale bars, 100 mm.DISCUSSION
In this paper, we describe a multi-step process to produce
gene-corrected hematopoietic cells including early progen-
itors and functional osteoclasts from iPSCs generated from
a preclinical mouse model of ARO.
Autologous HSC gene therapy represents an emerging
therapeutic opportunity for genetic diseases with hemato-
logical origin to avoid the requirement of compatible
donors. However, viral vector-mediated gene correction
of patient HSCs carry the risk of insertional mutagenesis
(Nienhuis, 2013) and unregulated transgene expression.
Gene correction by homologous recombination would
represent a major step forward; however, the difficulty of564 Stem Cell Reports j Vol. 5 j 558–568 j October 13, 2015 j ª2015 The Aex vivo expanding and/or selecting a small fraction of
gene-edited HSCs still represents a challenge. As an alterna-
tive to ex vivo HSCs, iPSCs represent an innovative source
of donor cells. They are pluripotent stem cells derived from
the reprogramming of somatic cells, so they have an easily
accessible cell source, obtainable without invasive proce-
dures. The feasibility to perform gene targeting is greater,
for their propensity to homologous recombination and
for the possibility of selecting and expanding clones where
gene editing has occurred.
In the present study, we tested the feasibility of gene-
correction technology using as donor a BAC engineered
vector. Taking advantage of the large genomic region car-
ried by this vector, the full-length form of Tcirg1 wasuthors
inserted, correcting the large mutation that causes the
phenotype in the mouse. Since in human ARO the TCIRG1
gene is mainly affected by point mutations located in
different positions within the gene locus, the use of a
BAC allows the utilization of the same donor vector for
every type of mutations found in TCIRG1-dependent pa-
tients. In contrast, targeted genome editing using artificial
nucleases would imply designing either a different donor
template for each mutation, or a single cDNA template,
thus not completely restoring the native locus including
introns and regulatory sequences.
We generated iPSCs using a third-generation self-inacti-
vating excisable lentiviral vector, which proved to be effica-
cious for obtaining vector-free pluripotent stem cells. More
recent techniques, such as the use of the non-integrating
Sendai virus, would allow production of iPSCs without all
the in vitro manipulations required for Cre-recombinase
excision, which include extensive sub-cloning and selec-
tion of vector-free and normal karyotype clones. All these
procedures could be skipped thus avoiding the risk of intro-
ducing additional mutations. Importantly, if pre-natal tis-
sues are used to generate patient-specific iPSCs, as proposed
by others (Anchan et al., 2011), autologous iPSC-mediated
cell therapy for ARO could be envisioned to treat patients at
birth, if not earlier, to prevent bone as well as secondary
neurological defects, which cannot be rescued if transplan-
tation is not performed soon after birth. Moreover, iPSCs
represent an unlimited supply of corrected cells for addi-
tional future use.
To evaluate the ability of WTand oc/oc corrected iPSCs to
form functional osteoclasts, a protocol for the hematopoi-
etic differentiation was set up, to obtain myeloid cells as
well as HSCs/early progenitors. Various differentiation
protocols have been described to obtain in vitro the he-
matopoietic lineage, but the only ones which provide
long-term stem cells utilize the overexpression of addi-
tional transcription factors, such as Hoxb4, Lhx2, or the
combination of Gata2, Gfi1b, cFos, and Etv6 (Hanna
et al., 2007, 2010; Takahashi and Yamanaka, 2006). The
overexpression of these factors represents an additional
manipulation and requires the use of integrating vectors
for the stable expression of transgenes. For this reason,
we opted to avoid the overexpression of supplementary
transgenes, thus inducing differentiation in more physio-
logical conditions. Indeed, in the presence of a hematopoi-
etic cytokine cocktail the EB method induces first the
mesoderm development at the expense of the other two
germ layers, and then pushes toward the hematopoietic
specification, likely through a hemogenic endothelium
intermediate. All tested clones behaved similarly in terms
of hematopoietic differentiation, with the exception of a
slight delay in the kinetics of myeloid differentiation in
oc/oc clones that was restored upon gene correction.Stem CellDespite all the efforts, the scientific community has not
yet reached the goal of reproducing in vitro the complex
microenvironment made of cells, cytokines, and signals
that sustains the correct HSC development. Accordingly,
we were not able to demonstrate engraftment of our
iPSC-derived hematopoietic progenitors in oc/oc recipient
mice (F. Ficara, unpublished data). Further amelioration
of the in vitro procedures aimed at obtaining a sufficient
number of safe, functional HSCs in a timely manner from
somatic cells going through a pluripotent intermediate is
therefore needed before iPSC research can be translated
in the clinical practice for the cure of diseases with hemato-
logical origin. Nevertheless, upon gene correction, oc/oc
iPSCs differentiated into hematopoietic progenitors and
then tomature osteoclasts able to efficiently resorb dentine
in vitro, demonstrating their fully functional correction.
Interestingly, it has been proposed that ARO infants could
benefit from early transplantation of myeloid progenitors
differentiated toward the osteoclast lineage (Cappariello
et al., 2010). In the mouse, this approach has been shown
to prevent defects in the formation of foramina, which
the optic and acoustic nerves pass through, thus reducing
visual and hearing defects. In this regard, autologous iPSCs
could provide an unlimited source of autologous mature
osteoclasts for repeated infusions.
Generation of iPSCs from patients who do not have
access to an HLA-identical donor could allow their site-spe-
cific genetic correction by homologous recombination, fol-
lowed by differentiation toward hematopoietic progenitors
and autologous transplantation. Further optimization of
protocols aimed at expanding in vitro hematopoietic pro-
genitors is needed to allow the clinical application of this
therapeutic approach to the clinical arena.EXPERIMENTAL PROCEDURES
Animals
C57BL/6J WT, congenic C57BL/6J-Ly5.1, B6C3Fe a/a Tcirg1 oc/
J-Ly5.2 (oc/oc), and non-obese diabetic-scid IL2rg(null) (NSG)
mice were purchased from Charles River Laboratories or Jackson
Laboratory. oc/oc-Ly5.1 mice were obtained after crossing of con-
genic Ly5.1 with oc/oc animals. Animal care and experimental pro-
cedures were performed in accordance with ethical rules by the
institutional review board.
Cells
Mouse embryonic fibroblasts (MEFs) to be used as feeder layer were
derived from WT embryonic day 13.5 embryos; WT iPSCs were
generated from Ly5.1 MEFs; oc/oc iPSCs were derived from oc/oc-
Ly5.1 mice fibroblasts obtained from tail biopsy. iPSC colonies
were co-cultured with Mitomycin C (Sigma)-treated MEFs and
passaged using Trypsin-EDTA 0.5% (Lonza) dissociation. They
were cultured in ES medium, containing Knockout-DMEM
(Gibco), 15% embryonic stem cell-qualified fetal bovine serumReports j Vol. 5 j 558–568 j October 13, 2015 j ª2015 The Authors 565
(ES-FBS, Life Technologies), 100 U/ml P/S (Lonza), 2 mM L-gluta-
mine (Lonza), b-mercaptoethanol (Life Technologies), 1 3 non-
essential amino acids (1003, Life Technologies) supplemented
with 103 U/ml leukemia inhibitor factor (LIF, Millipore). Medium
was changed daily. All steps were performed maintaining cells at
37C with 5% CO2.
Reprogramming Procedure
Fibroblastswere reprogrammed by an overnight infection atMOI =
1 in the presence of 4 ng/ml polybrene (Sigma) with a third-
generation lentiviral vector carrying LoxP sites in the sinLTRs
and expressing the Oct4, Sox2, and Klf4 reprogramming factors.
The following day, the medium was replaced and after 48 hr cells
were seeded onto MEF feeder layer with ES medium, which was
changed daily. iPSC-like colonies were individually picked 4 weeks
later, with a reprogramming efficiency of 0.01%. To excise the
vector, iPSCs were transfected with plasmid DNA expressing the
Cre recombinase cDNA in presence of Lipofectamine 2000 (Life
Technologies) at a 1:3 ratio (pDNA:Lipofectamine 2000). After a
week, iPSCs were subcloned at a limiting dilution to obtain clonal
lines.
Gene Correction
The RP24-241G10 BAC (containing the entire WT Tcirg1 genomic
region) belonging to the RPCI-24 C57BL/6Jmouse BAC library was
purchased from Children’s Hospital Oakland Research Institute
(CHORI). A neo resistance cassette surrounded by FRT sites was
inserted in intron 10 of the Tcirg1 gene (Gene Bridges). After an
overnight BAC transfection in the presence of Lipofectamine
2000 on aMEF feeder layer, cells were transferred on DR4-resistant
MEFs (Applied StemCell), and neomycin was added the following
day. We obtained and successfully isolated neomycin resistant
colonies in all experiments.
In order to avoid possible MEFs contamination in PCR analysis,
all clones were purified with anti-SSEA-1 (stage-specific embryonic
antigen-1)magnetic beads (Miltenyi Biotec) according to theman-
ufacturer’s instructions and passaged three times on gelatin-coated
plates before collecting genomic DNA and RNA for analysis.
For excision of the Neo resistance cassette from clone 13.62.18,
the pCAG-Flpe plasmid (Addgene) was transfected in the presence
of Lipofectamine 2000. Clones were cultured with or without
neomycin and those that were not resistant were isolated and
further expanded.
Alkaline Phosphatase Staining
Leucocyte Alkaline Phosphatase Kit (Sigma-Aldrich) was used,
accordingly to kit instructions.
Chromosome Preparations and Analysis
Chromosome analysis was performed on slide preparation of cells
grown on coverslips. Briefly, cell cultures were treated with colchi-
cine (KaryoMAX colcemid solution, Life Technologies) at a final
concentration of 0.1 mg/ml for 2 hr at 37C. After hypotonic
treatment with 0.075 M KCl and fixation in methanol:acetic acid
(3:1 v/v), slides were air-dried and mounted with Eukitt mounting
medium (Sigma-Aldrich). Chromosome counts and karyotype
analyses were performed on metaphases stained with Vectashield566 Stem Cell Reports j Vol. 5 j 558–568 j October 13, 2015 j ª2015 The AmountingmediumwithDAPI (Vector Laboratories) for G-banding.
Images were captured using an Olympus BX61 Research Micro-
scope equipped with a cooled charge-coupled device (CCD)
camera and analyzed with Applied Imaging Software CytoVision
(CytoVision Master System with mouse karyotyping).
FISH Assay
The BAC RP24-241G10 (mapping to the proximal region of the
mouse chromosome 19) was used as DNA probe and labeled via
nick translation (Life Technologies), using Spectrum Orange-
dUTP (Vysis). The labeled probe was resuspended in the hybridi-
zation buffer (50% formamide, 10% dextran sulfate, 1 3 Den-
hart’s solution, 0.1% SDS, 40 mM Na2HPO4 [pH 6.8], 2 3 saline
sodium citrate [SSC]) containing 103 mouse Cot1 DNA (Life
Technologies), denatured at 80C for 10 min, and pre-annealed
at 37C for 20 min before hybridization. Slides were treated
with Pepsin (0.004%) at 37C for 30 s and dehydrated through
the ethanol series before denaturation in 70% formamide/2 3
SSC. Hybridization was done overnight at 37C. Stringent wash-
ings were done in 50% formamide/2 3 SSC at 42C. Slides were
mounted in Vectashield mounting medium with DAPI and then
scored under an Olympus BX61 Research Microscope equipped
with a cooled CCD camera. Images were captured and analyzed
with Applied Imaging Software CytoVision (CytoVision Master
System with Karyotyping and FISH). At least 20 images were
analyzed for each clone.
In Vitro Germ Layer Differentiation
EBs were obtained by culturing 1,500 iPSCs in 20 ml hanging drops
in ES medium without LIF for 2 days, before seeding on gelatin-
coated coverslips in 24-well plates.
After 5 days of culture, an immunofluorescence was performed
on part of the cells using antibodies against Alphafetoprotein
(1:50, AFP, R&D Systems, MAB1368) and Brachyury (1:100, Ab-
cam, ab20680). The remaining cells were treated with retinoic
acid (PeproTech) to induce ectoderm differentiation. After
19 days of culture, immunofluorescence was performed using an
antibody against Nestin (1:100, Abcam, ab11306). To further vali-
date mesoderm differentiation, EBs were seeded at day 5 of differ-
entiation and checked for cardiomyocyte beating activity starting
from day 7.
Immunofluorescence
iPSCs or EBs were seeded on 0.1% gelatin-coated glass coverslips in
24-well culture dishes and fixed with 4% paraformaldehyde (PFA)
in PBS for 15 or 20 min at room temperature, washed twice with
PBS, and then permeabilized with 0.1% Triton X-100 in PBS for
5 min. After 1 hr in blocking solution (5% FBS in PBS), iPSCs
were incubated with primary antibodies directed against Oct4
(1:200, Abcam, ab18976), Sox2 (1:200, Abcam, ab97959), Nanog
(1:100, Novus Biologicals, NB100-58842) or SSEA-1 (1:100, Cell
Signaling, MC480), and EBs with antibodies directed against AFP,
Brachyury, or Nestin followed by repeatedwashing and incubation
with secondary antibodies (goat anti-mouse immunoglobulin G
(IgG) (H+L) or goat anti-rabbit IgG (H+L), Invitrogen). Nuclei
were counterstained with DAPI and mounted with ProLong Gold
antifade reagent (Life Technologies).uthors
Teratoma Formation and Blastocyst Injection
5 3 106 iPSCs were subcutaneously injected in NSG mice. Two/
three weeks later, mice were sacrificed, and dissected nodules
were fixed with 4% formaline and embedded in paraffine for
H&E staining. For the chimera assay, 32-BAC clone (passage 12
from BAC-mediated correction) was injected into albino C57BL/
6 host blastocysts in the Mouse Mutant Core Facility of the Insti-
tute for Research in Biomedicine (IRB) in Barcelona. Chimerism
was assessed after birth by the appearance of black coat color
over the white background of the host pups.
Differentiation to the Hematopoietic Lineage
800-cell EBs were formed in hanging drops in culture medium
without LIF. At day 2, EBs were transferred into tissue-culture
plates, and the following cytokines were added to induce differen-
tiation: 50 ng/ml m-BMP4, 30 ng/ml m-VEGF164 (both from
R&D), 50 ng/ml m-SCF, 50 ng/ml h-Flt3L, 10 ng/ml m-IL-3,
10 ng/ml m-IL-6, and 10 ng/ml m-GM-CSF (all from PeproTech).
At day 4 and 8, fresh medium was added with the same cytokine
cocktail with the exception of m-BMP4. FACS analyses were per-
formed from day 8 to 12 of culture in most experiments.
Colony Forming Cell Assay
At the end of the above described hematopoietic differentiation,
progenitors were purified with anti-cKit magnetic beads (Miltenyi
Biotec) and seeded into methylcellulose-containing medium
(methoCult 3234; STEMCELL Technologies) in the presence of
the following cytokines: 3 U/ml h-EPO (R&D), 20 ng/ml m-SCF,
20 ng/ml h-Flt3L, 10 ng/ml m-IL-3, 10 ng/ml m-IL-6, 10 ng/ml
m-GM-CSF, and 10 ng/ml m-TPO (all purchased from PeproTech),
and colonies were scored at day 10. Representative colonies were
cytospun, and cell types were determined after May-Grunwald-
Giemsa staining (Carlo Erba).
Osteoclast Differentiation
CD45+ cells were purified from iPSC-derived hematopoietic cells
by magnetic beads (Miltenyi Biotec) and were cultured for a week
inMinimal Essential Medium AlphaModification (aMEM, Gibco),
10% FBS, 100U/ml P/S, 2mML-glutamine in presence of 20 ng/ml
m-SCF and 100 ng/ml m-M-CSF (PeproTech). Cells were subse-
quently transferred either on flat-bottomed 96-well tissue culture
plates or on dentine slices (Osteosite, iDS, Pantec) and cultured
in the same medium supplemented with 20 ng/ml m-M-CSF and
30 ng/ml m-RANKL (PeproTech). When osteoclasts were visible
on tissue culture plates (after 5–10 days of culture), they were fixed
and stained with tartrate resistance acid phosphatase (TRAP) assay
(Sigma-Aldrich: acid phosphatase, leukocyte) accordingly to man-
ufacturer’s instructions, while dentine slices were stained with 1%
toluidine blue for 3 min and then washed in water. A similar pro-
tocol was pursued with oc/oc or WT mice freshly isolated spleno-
cytes or BM cells, after purification of CD11b+ (instead of CD45+)
cells by magnetic beads (Miltenyi Biotec).
Flow Cytometry
Staining of cells for FACS analysis was performed in PBS con-
taining 2% fetal calf serum and 1 mM EDTA, with the following
conjugated monoclonal antibodies (mAbs) obtained from eitherStem CelleBioscience or Pharmingen: CD11b (M1/70, 553312 or 53-0112-
82), CD31 (390, 12-0311-83), pan-CD45 (30/F11, 12-0451-82),
CD41 (eBioMWReg30, 48-0411), F4/80 (BM8, 25-4801-82), Ly6C
(AL-21, 553104), Ly6G (RB6-8C5, 17-5931-81). LSR Fortessa or
FACS Canto II flow cytometers equipped with Diva software (BD)
were used for data acquisition and FlowJo software (Tree Star)
was employed for data analysis.
Unstained and/or FMO (fluorescence minus one) samples were
employed to set gates for FACS analysis.
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